We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2200 - 0.3198|
|52 Week Range||0.1700 - 3.1300|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
This is a summary of a request from the official committee of unsecured creditors of Orexigen Therapeutics Inc. to hire Irell & Manella LLP as counsel, filed April 27 with the U.S. Bankruptcy Court in ...
The offer, revealed Monday in a filing in U.S. Bankruptcy Court in Wilmington, Del., is subject to higher bids at a court-supervised auction. The deal would include the world-wide rights to anti-obesity drug Contrave. to name the investor group’s acquisition vehicle, Nalpropion Pharmaceuticals Inc., as the stalking horse, or lead bidder, at the auction.
SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially all of the assets of the company, subject to court approval. Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave® (naltrexone HCl / bupropion HCl extended release) /Mysimba™ (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for $75 million in cash. The deal is subject to higher and better offers.
This is a summary of a request from Orexigen Therapeutics Inc. to hire Morris Nichols Arsht & Tunnell LLP as Delaware bankruptcy co-counsel, filed March 23 with the U.S. Bankruptcy Court in Wilmington, ...
Orexigen Therapeutics Inc (NASDAQ:OREX), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS in the over the last fewRead More...
The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
|Downgrade||JMP Securities: to Market Perform||3/16/2016|
|Downgrade||JP Morgan: to Neutral||2/29/2016|
|Downgrade||RBC Capital: to Sector Perform||2/29/2016|
|Downgrade||Leerink Swann: to Market Perform||2/23/2016|
|Downgrade||Wallachbeth: to Hold||12/16/2015|
|Initiated||Bank of America: to Underperform||12/11/2015|
Industry: Drug Manufacturers - Other
Full Time Employees: 132
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.